A Study to See if AZLI (an Inhaled Antibiotic) is Effective in Treating Adults With Non-CF Bronchiectasis - AIR-BX2

This study has been completed.
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
First received: March 11, 2011
Last updated: August 26, 2013
Last verified: August 2012

The AIR-BX-2 study is for people who have been diagnosed with non-CF bronchiectasis and have gram-negative airway infection. This is a randomized study, the participants will be selected by chance (like flipping a coin) to receive one of two treatments (AZLI or Placebo). This is a double-blind study which means participants and their study doctors will not know what treatment they are assigned to receive. Participants will receive two 28 day courses of either AZLI or placebo taken 3 times a day. Each course has a 28 day off-drug period. Following the blinded courses, all participants will receive AZLI for the third 28 day course.

Based on observed safety and effectiveness of AZLI in the adult CF population, and due to the similarities in the lung disease for patients with CF and non-CF bronchiectasis, AZLI represents a potential treatment for people with non-CF bronchiectasis and infection of the airways.

Condition Intervention Phase
Drug: Aztreonam for Inhalation Solution (AZLI)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Change in QOL-B Respiratory Symptoms Score [ Time Frame: Baseline to end of treatment course 1 (Day 28) ] [ Designated as safety issue: No ]
    Change in the Respiratory Symptoms score on the Quality of Life Questionaire-Bronchiectasis(QOL-B) from baseline to the end of the placebo-controlled course 1 treatment with AZLI or placebo (Day 28)

Secondary Outcome Measures:
  • Change in QOL-B Respiratory Symptoms and Physical Functioning Scores [ Time Frame: Baseline to end of treatment course 1 and 2. ] [ Designated as safety issue: No ]
  • Time to Exacerbation [ Time Frame: From baseline to open label treatment (4 months) ] [ Designated as safety issue: No ]
    Time to protocol defined exacerbation prior to open-label AZLI treatment.

Enrollment: 274
Study Start Date: April 2011
Study Completion Date: July 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AZLI Drug: Aztreonam for Inhalation Solution (AZLI)
75 mg Aztreonam lysine monohydrate administered via nebulizer, three times a day for a 28 day period.
Placebo Comparator: Sugar and Saline Solution Drug: Placebo
Sugar powder reconstituted with diluent and administered via nebulizer, three times a day for a 28 day period.

Detailed Description:

There will be 10 scheduled study visits. Planned visits include screening prior to randomization, evaluations at 14-day intervals during the first placebo-controlled course, and every 28 days subsequently.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male/Female 18 years or older with non-CF bronchiectasis
  • Chronic sputum production on most days
  • Positive sputum culture for gram-negative organisms
  • Must meet lung function requirements

Exclusion Criteria:

  • History of CF
  • Hospitalized within 14 days prior to joining the study
  • Previous exposure to AZLI for inhalation
  • Pregnant, breastfeeding or unwilling to follow contraceptive measures for the study
  • Must meet liver and kidney function requirements
  • Continuous oxygen use of greater than 2 Liters per minute (supplemental oxygen with activity and at night is allowed)
  • Current treatment for nontuberculous mycobacteria infection or active mycobacterium tuberculosis infection within 1 year of enrollment
  • Other serious medical conditions
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01314716

  Show 85 Study Locations
Sponsors and Collaborators
Gilead Sciences
Principal Investigator: Anne O'Donnell, MD Georgetown University Hospital
  More Information

No publications provided

Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT01314716     History of Changes
Other Study ID Numbers: GS-US-219-0104
Study First Received: March 11, 2011
Last Updated: August 26, 2013
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Spain: Spanish Agency of Medicines
Netherlands: Medicines Evaluation Board (MEB)
Italy: The Italian Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Belgium: Federal Agency for Medicinal Products and Health Products

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 14, 2014